Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L
Department of Endocrinology and Metabolism C, Aarhus Sygehus, Aarhus University Hospital, Aarhus, Denmark.
J Intern Med. 2005 Feb;257(2):176-84. doi: 10.1111/j.1365-2796.2004.01434.x.
Loop diuretics (LD) are widely used in the treatment of cardiovascular diseases and disorders with fluid accumulation. LD are known to increase renal calcium losses and may thereby affect calcium homeostasis and bone metabolism.
We studied to what extent long-term treatment with LD affects calcium homeostasis and bone metabolism.
In a cross-sectional design we compared 140 postmenopausal women treated with a LD for more than 2 years with 140 age-matched women not in diuretic therapy.
Treatment with LD was associated with significantly increased urinary calcium, plasma parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D levels. Per 40 mg day(-1) of furosemide, urinary calcium was increased by 17% (P < 0.05) and plasma PTH levels were increased by 28% (P = 0.04). Users of LD had a 17% higher body weight (P < 0.001) compared with nonusers. This was due to a 32% higher fat mass (P < 0.001) and a 6% higher lean tissue mass (P < 0.001). Moreover, users of LD had a higher bone mineral density (BMD) at the spine (+7.5%, P < 0.001), hip (+4.8%, P = 0.004), forearm (+3.7%, P = 0.01) and whole body (+2.5%, P = 0.06). However, after adjustment for body weight differences, BMD did not differ between groups. Nevertheless, duration of LD treatment was positively associated with BMD at the spine (P = 0.03) and whole body (P < 0.05). BMD at the spine increases by 0.3% per 1 year of treatment.
The increased renal calcium losses in users of LD are compensated for by a PTH-dependent increase in 1,25(OH)(2)D levels. Thereby calcium balance remains neutral without major effects on bone metabolism.
袢利尿剂(LD)广泛用于治疗心血管疾病以及伴有体液潴留的病症。已知LD会增加肾脏钙流失,从而可能影响钙稳态和骨代谢。
我们研究了长期使用LD在多大程度上会影响钙稳态和骨代谢。
采用横断面设计,我们将140名接受LD治疗超过2年的绝经后女性与140名年龄匹配的未接受利尿剂治疗的女性进行了比较。
使用LD治疗与尿钙、血浆甲状旁腺激素(PTH)和1,25 - 二羟基维生素D水平显著升高相关。每40毫克/天的呋塞米,尿钙增加17%(P < 0.05),血浆PTH水平增加28%(P = 0.04)。与未使用者相比,LD使用者体重高17%(P < 0.001)。这是由于脂肪量高32%(P < 0.001)和瘦组织量高6%(P < 0.001)。此外,LD使用者在脊柱(+7.5%,P < 0.001)、髋部(+4.8%,P = 0.004)、前臂(+3.7%,P = 0.01)和全身(+2.5%,P = 0.06)的骨密度(BMD)更高。然而,在对体重差异进行校正后,两组之间的BMD没有差异。尽管如此,LD治疗的持续时间与脊柱(P = 0.03)和全身(P < 0.05)的BMD呈正相关。每治疗1年,脊柱的BMD增加0.3%。
LD使用者肾脏钙流失增加,通过PTH依赖的1,25(OH)₂D水平升高得到补偿。从而钙平衡保持中性,对骨代谢无重大影响。